• Je něco špatně v tomto záznamu ?

Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling

L. Sivák, V. Šubr, J. Kovářová, B. Dvořáková, M. Šírová, B. Říhová, E. Randárová, M. Kraus, J. Tomala, M. Studenovský, M. Vondráčková, R. Sedláček, P. Makovický, J. Fučíková, Š. Vošáhlíková, R. Špíšek, L. Kostka, T. Etrych, M. Kovář

. 2021 ; 332 (-) : 563-580. [pub] 20210312

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025855

Drug repurposing is a promising strategy for identifying new applications for approved drugs. Here, we describe a polymer biomaterial composed of the antiretroviral drug ritonavir derivative (5-methyl-4-oxohexanoic acid ritonavir ester; RD), covalently bound to HPMA copolymer carrier via a pH-sensitive hydrazone bond (P-RD). Apart from being more potent inhibitor of P-glycoprotein in comparison to ritonavir, we found RD to have considerable cytostatic activity in six mice (IC50 ~ 2.3-17.4 μM) and six human (IC50 ~ 4.3-8.7 μM) cancer cell lines, and that RD inhibits the migration and invasiveness of cancer cells in vitro. Importantly, RD inhibits STAT3 phosphorylation in CT26 cells in vitro and in vivo, and expression of the NF-κB p65 subunit, Bcl-2 and Mcl-1 in vitro. RD also dampens chymotrypsin-like and trypsin-like proteasome activity and induces ER stress as documented by induction of PERK phosphorylation and expression of ATF4 and CHOP. P-RD nanomedicine showed powerful antitumor activity in CT26 and B16F10 tumor-bearing mice, which, moreover, synergized with IL-2-based immunotherapy. P-RD proved very promising therapeutic activity also in human FaDu xenografts and negligible toxicity predetermining these nanomedicines as side-effect free nanosystem. The therapeutic potential could be highly increased using the fine-tuned combination with other drugs, i.e. doxorubicin, attached to the same polymer system. Finally, we summarize that described polymer nanomedicines fulfilled all the requirements as potential candidates for deep preclinical investigation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025855
003      
CZ-PrNML
005      
20211026133438.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jconrel.2021.03.015 $2 doi
035    __
$a (PubMed)33722611
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Sivák, Ladislav $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
245    10
$a Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling / $c L. Sivák, V. Šubr, J. Kovářová, B. Dvořáková, M. Šírová, B. Říhová, E. Randárová, M. Kraus, J. Tomala, M. Studenovský, M. Vondráčková, R. Sedláček, P. Makovický, J. Fučíková, Š. Vošáhlíková, R. Špíšek, L. Kostka, T. Etrych, M. Kovář
520    9_
$a Drug repurposing is a promising strategy for identifying new applications for approved drugs. Here, we describe a polymer biomaterial composed of the antiretroviral drug ritonavir derivative (5-methyl-4-oxohexanoic acid ritonavir ester; RD), covalently bound to HPMA copolymer carrier via a pH-sensitive hydrazone bond (P-RD). Apart from being more potent inhibitor of P-glycoprotein in comparison to ritonavir, we found RD to have considerable cytostatic activity in six mice (IC50 ~ 2.3-17.4 μM) and six human (IC50 ~ 4.3-8.7 μM) cancer cell lines, and that RD inhibits the migration and invasiveness of cancer cells in vitro. Importantly, RD inhibits STAT3 phosphorylation in CT26 cells in vitro and in vivo, and expression of the NF-κB p65 subunit, Bcl-2 and Mcl-1 in vitro. RD also dampens chymotrypsin-like and trypsin-like proteasome activity and induces ER stress as documented by induction of PERK phosphorylation and expression of ATF4 and CHOP. P-RD nanomedicine showed powerful antitumor activity in CT26 and B16F10 tumor-bearing mice, which, moreover, synergized with IL-2-based immunotherapy. P-RD proved very promising therapeutic activity also in human FaDu xenografts and negligible toxicity predetermining these nanomedicines as side-effect free nanosystem. The therapeutic potential could be highly increased using the fine-tuned combination with other drugs, i.e. doxorubicin, attached to the same polymer system. Finally, we summarize that described polymer nanomedicines fulfilled all the requirements as potential candidates for deep preclinical investigation.
650    _2
$a zvířata $7 D000818
650    12
$a antitumorózní látky $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a doxorubicin $7 D004317
650    _2
$a koncentrace vodíkových iontů $7 D006863
650    _2
$a myši $7 D051379
650    _2
$a nanomedicína $7 D050997
650    12
$a polymery $7 D011108
650    _2
$a proteasomový endopeptidasový komplex $7 D046988
650    _2
$a ritonavir $7 D019438
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Šubr, Vladimír $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czech Republic
700    1_
$a Kovářová, Jiřina $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Dvořáková, Barbora $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Šírová, Milada $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Říhová, Blanka $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Randárová, Eva $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czech Republic
700    1_
$a Kraus, Michal $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Tomala, Jakub $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Studenovský, Martin $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czech Republic
700    1_
$a Vondráčková, Michaela $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic
700    1_
$a Sedláček, Radislav $u Czech Center of Phenogenomics, Institute of Molecular Genetics, Czech Academy of Sciences, v.v.i., Prumyslova 595, 25250 Vestec, Czech Republic
700    1_
$a Makovický, Petr $u Czech Center of Phenogenomics, Institute of Molecular Genetics, Czech Academy of Sciences, v.v.i., Prumyslova 595, 25250 Vestec, Czech Republic
700    1_
$a Fučíková, Jitka $u Department of Immunology, Charles University, 2(nd) Faculty of Medicine and University Hospital Motol, V uvalu 84, 15006 Prague, Czech Republic; Sotio, Jankovcova 1518, 17000 Prague, Czech Republic
700    1_
$a Vošáhlíková, Šárka $u Sotio, Jankovcova 1518, 17000 Prague, Czech Republic
700    1_
$a Špíšek, Radek $u Department of Immunology, Charles University, 2(nd) Faculty of Medicine and University Hospital Motol, V uvalu 84, 15006 Prague, Czech Republic; Sotio, Jankovcova 1518, 17000 Prague, Czech Republic
700    1_
$a Kostka, Libor $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czech Republic
700    1_
$a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, v.v.i., Heyrovskeho nam. 2, 16206 Prague, Czech Republic. Electronic address: etrych@imc.cas.cz
700    1_
$a Kovář, Marek $u Institute of Microbiology, Czech Academy of Sciences, v.v.i., Videnska 1083, 14220 Prague, Czech Republic. Electronic address: makovar@biomed.cas.cz
773    0_
$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 332, č. - (2021), s. 563-580
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33722611 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133444 $b ABA008
999    __
$a ok $b bmc $g 1714762 $s 1146362
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 332 $c - $d 563-580 $e 20210312 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace